Molecular-targeted agents in pancreatic cancer (Q35641998)

9 August 2017

1 reference

title

Molecular-targeted agents in pancreatic cancer (English)

1 reference

9 August 2017

1 reference

Everardo D Saad

1

1 reference

9 August 2017

Paulo M Hoff

series ordinal

2

1 reference

9 August 2017

publication date

1 January 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

11

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

32-38

1 reference

9 August 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Development of matrix metalloproteinase inhibitors in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

A phase II trial of marimastat in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

The epidermal growth factor receptor as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Overexpression of HER2/neu oncogene in human pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Smart drugs: tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Prognostic significance of angiogenesis in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Immunotherapy for pancreatic cancer: current concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480401100105

10.1177/107327480401100105

21 January 2018

Identifiers

DOI

0 references

1 reference